Homograft Aortic Root Replacement

동종이식편을 이용한 대동맥 근부 치환술

  • Kim Jae Hyun (Department of Thoracic and Cardiovascular Surgery, Sejong General Hospital, Sejong Heart Institute) ;
  • Oh Sam Sae (Department of Thoracic and Cardiovascular Surgery, Sejong General Hospital, Sejong Heart Institute) ;
  • Lee Chang-Ha (Department of Thoracic and Cardiovascular Surgery, Sejong General Hospital, Sejong Heart Institute) ;
  • Baek Man Jong (Department of Thoracic and Cardiovascular Surgery, Sejong General Hospital, Sejong Heart Institute) ;
  • Kim Chong Whan (Department of Thoracic and Cardiovascular Surgery, Sejong General Hospital, Sejong Heart Institute) ;
  • Na Chan-Young (Department of Thoracic and Cardiovascular Surgery, Sejong General Hospital, Sejong Heart Institute)
  • 김재현 (부천세종병원 흉부외과, 세종심장연구소) ;
  • 오삼세 (부천세종병원 흉부외과, 세종심장연구소) ;
  • 이창하 (부천세종병원 흉부외과, 세종심장연구소) ;
  • 백만종 (부천세종병원 흉부외과, 세종심장연구소) ;
  • 김종환 (부천세종병원 흉부외과, 세종심장연구소) ;
  • 나찬영 (부천세종병원 흉부외과, 세종심장연구소)
  • Published : 2005.03.01

Abstract

Homograft aortic valve replacement (AVR) has many advantages such as excellent hemodynamic performance, faster left ventricular hypertrophy regression, resistance to infection and excellent freedom of thromboembolism. To find out the results of homograft AVR, we reviewed our surgical experiences. Material and Method: Eighteen patients (male female=16 : 2, mean age=39.3$\pm$16.2 years, range: 14$\~$68 years) who underwent homo-graft aortic valve replacement between May 1995 and May 2004 were reviewed. The number of homografts was 20 (17 aortic and 3 pulmonic homografts) including two re-operations. Ten patients had a history of previous aortic valve surgery. Indications for the use of a homograft were native valve endocarditis (n=7), prosthetic valve endocarditis (n=5), or Behcet's disease (n=8). The homograft had been implanted predominantly as a full root except in one patient in the subcoronary position. Result: Mean follow-up was 41.3 $\pm$ 26.2 months. There was one operative mortality. Postoperative complications included postoperative bleeding in 3 patients, and wound infection in 1. There was no late death. Three patients underwent redo-AVR. The etiology of the three reoperated patients was Behcet's disease (p=0.025). Freedom from reoperation was $87.5\pm8.3\%$, $78.8\pm11.2\%$ at 1, 5 years respectively, In patients with infective endocarditis, there was no recurrence of endocarditis. There was no thromboembolic complication. Conclusion: Although longer term follow-up with larger numbers of patients is necessary, the operative and mid-term results for homograft AVR was good when we took into account the operative risks of Behcet's disease or infective endocarditis. Behest's disease was a risk factor for reoperation after the homograft AVR. We think homograft AVR is the procedure of choice, particularly in patients with infective endocarditis.

대동맥판막 치환술 시 사용되는 동종이식편은 훌륭한 혈역학적 기능과 우수한 좌심실 근육량 감소(enhanced left ventricular mass regression), 감염에 대한 내성, 혈색전증 발생 위험이 적다는 등의 많은 장점들이 있다. 저자들은 본원에서 시행한 동종이식편을 이용한 대동맥판막 치환술의 결과를 알아보고자 한다. 방법 및 대상: 1995년 5월부터 2004년 5월까지 18명의 환자(남 : 여=16 : 2, 평균 연령=39.3$\pm$16.2세, 연령 범위 14$\~$68세)에서 동종이식편을 이용한 대동맥판막 치환술은 20예가 시행되었다. 2예의 재수술을 포함하여 대동맥 동종이식편이 17개 사용되었고 폐동맥 동종이식편이 3개 사용되었다. 대동맥 판막에 대한 수술 과거력이 있는 환자는 10명이었다. 동종이식편 사용의 적응증으로는 자가판막 심내막염(n=7), 인공심장판막 심내막염(n=5), 혹은 Behcet 병에 동반된 대동맥판막 질환(n=8) 이었다. 수술방법은 관상동맥하 삽입술(subcoronary implantation)을 시행한 1명을 제외한 모든 환자에서 완전 근부 치환술(full root replacement)을 이용하였다. 결과 : 평균 관찰기간은 41.3$\pm$26.2 개월이었다. 수술사망이 1예 있었으며 합병증으로는 수술 후 출혈이 3예, 총격동염이 1예 발생하였다. 만기 사망 예는 없었으며 3예에서 대동맥판막 재치환술을 시행하였고 3명이 모두 Behcet 병 환자였다(p=0.025). 재수술에 대한 자유도는 1년과 5년에 각각 $87.5\pm8.3\%$, $78.8\pm11.2\%$였다. 심내막염 환자들에서 수술 후 심내막염의 재발은 없었다. 관찰 기간 중 항응고 요법은 사용하지 않았고 판막에 의한 혈색전증은 관찰되지 않았다. 결론: Behcet병과 감염성 심내막염의 수술 위험도를 고려할 때 동종이식편 대동맥판막 치환술의 수술결과 및 술 후 관찰 결과는 양호하였다. Behcet 병은 동종이식편을 이용한 대동맥판막 치환술 후 재수술의 위험요인이었다. 심내막염 환자들에서 동종이식편 대동맥판막 치환술은 최선의 수술방법이라고 생각하며 더 많은 수의 환자들을 대상으로 장기 관찰이 필요할 것이다.

Keywords

References

  1. Eriksson MJ, Kallner G, Rosfors S, Ivert T, Brodin L. Hemodynamic performance of cryopreserved aortic homograft vlaves during midterm follow-up. J Am Coll Cardiol 1998;32:1002-8 https://doi.org/10.1016/S0735-1097(98)00352-0
  2. Hasegawa J, Kitamura S, Taniguchi S, et al. Comparative rest and exercise hemodynamics of allograft and prosthetic valves in the aortic position. Ann Thorac Surg 1997;64: 1753-6 https://doi.org/10.1016/S0003-4975(97)01035-7
  3. Maselli D, Pizio R, Bruno LP, Bella ID, Gasperis CD. Left ventricular mass reduction after aortic valve replacement: homografts, stentless and stented valves. Ann Thorac Surg 1999;67:966-71 https://doi.org/10.1016/S0003-4975(99)00215-5
  4. Xu YJ, Zhong-Ming Z, Gibson DG, Yacoub MH, Pepper JR. Effects of valve substitute on changes in left ventricular function and hypertrophy after aortic valve replacement. Ann Thorac Surg 1996;62:683-90 https://doi.org/10.1016/S0003-4975(96)00438-9
  5. Langley SM, McGuirk SP, Chaudhry MA, et al. Twenty- year follow-up of aortic valve replacement with antibiotic sterilized homografts in 200 patients. Semin Thorac Cardiovasc Surg 1999;11:28-34
  6. O'Brien MF, Harrocks S, Stafford EG, et al. The homograft aortic valve: a 29-year, 99.3% follow up of 1,022 valve replacement. J Heart Valve Dis 2001;10:334-44
  7. Ross DN. Homograft replacement of the aortic valve. Lancet 1962;2:487
  8. Barratt-Boyes BG. Homograft aortic valve replacement in aortic incompetence and stenosis. Thorax 1964;19:131-50 https://doi.org/10.1136/thx.19.2.131
  9. Fischlein T, Schutz A, Haushofer M, et al. Immunologic reaction and viability of cryopreserved homografts. Ann Thorac Surg 1995;60:122-6 https://doi.org/10.1016/S0003-4975(95)00384-3
  10. O'Brien MF, Stafford EG, Gardner MAH, Pohlner PG, McGiffin DC. A comparison of aortic valve replacement with viable cryopreserved and fresh allograft valves, with a note on chromosomal studies. J Thorac Cardiovasc Surg 1987;94:812-23
  11. Kirklin JK, Smith D, Novick W, et al. Long-term function of cryopreserved aortic homografts. a ten-year study. J Thorac Cardiovasc Surg 1993;106:154-65
  12. Dearani JA, Orszulak TA, Schaff HV, et al. Results of allograft aortic valve replacement for complex endocarditis. J Thorac Cardiovasc Surg 1997;113:285-91 https://doi.org/10.1016/S0022-5223(97)70325-8
  13. Niwaya K, Knott-Craig CJ, Santangelo K, et al. Advantages of autograft and homograft valve replacement for complex aortic valve endocarditis. Ann Thorac Surg 1999;67:1603-8 https://doi.org/10.1016/S0003-4975(99)00402-6
  14. Yankah AC, Klose H, Petzina R, et al. Surgical management of acute aortic root endocarditis with viable homograft; 13-year experience. Eur J Cardiothorac Surg 2002; 21:260-7 https://doi.org/10.1016/S1010-7940(01)01084-3
  15. Hampton CR, Chong AJ, Verrier ED. Stentless aortic valve replacement: homograft/autograft. In: Cohn LH, Edmunds LH. Cardiac surgery in the adult. 2nd ed. USA: McGraw-Hill Co. 2003;867-88
  16. Lim CY, Lee HJ, Kim JE. Aortic root replacement using aortic homograft in acute bacterial endocarditis -one case report-. Korean J Thorac Cardiovasc Surg 1997;30:819-22
  17. Lund O, Chandrasekaran V, Grocott-Mason R, et al. Primary aortic valve replacement with allografts over twenty- five years: valve related and procedure related determinants of outcome. J Thorac Cardiovasc Surg 1999;117:77-91 https://doi.org/10.1016/S0022-5223(99)70471-X